(Q92857461)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948174%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

title

Tuberculosis vaccine candidates based on mycobacterial cell envelope components (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948174%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948174%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Armando Acosta

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948174%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

author name string

M E Sarmiento

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948174%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

N Alvarez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948174%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

F Bigi

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948174%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

Y Tirado

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948174%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

M A García

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948174%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

F Z Anis

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948174%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

M N Norazmi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948174%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

publication date

22 January 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948174%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948174%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

volume

115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948174%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

page(s)

26-41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948174%20AND%20SRC:MED&resulttype=core&format=json

Mycobacterium tuberculosis: An Adaptable Pathogen Associated With Multiple Human Diseases.

2 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Tuberculosis vaccines: Opportunities and challenges.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Vaccine against tuberculosis: what's new?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Variation in protection by BCG: implications of and for heterologous immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Exploiting the mycobacterial cell wall to design improved vaccines against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Chapter 2: Biogenesis of the cell wall and other glycoconjugates of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The Envelope of Mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Identification of a gene involved in the biosynthesis of cyclopropanated mycolic acids in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The Mycobacterium tuberculosis virulence factor trehalose dimycolate imparts desiccation resistance to model mycobacterial membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The capsule of Mycobacterium tuberculosis and its implications for pathogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The glycan-rich outer layer of the cell wall of Mycobacterium tuberculosis acts as an antiphagocytic capsule limiting the association of the bacterium with macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Deficiency in mycolipenate- and mycosanoate-derived acyltrehaloses enhances early interactions of Mycobacterium tuberculosis with host cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The outermost capsular arabinomannans and other mannoconjugates of virulent and avirulent tubercle bacilli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The 19-kDa Mycobacterium tuberculosis protein induces macrophage apoptosis through Toll-like receptor-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A mutant of Mycobacterium tuberculosis lacking the 19-kDa lipoprotein Rv3763 is highly attenuated in vivo but retains potent vaccinogenic properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Antigen 85 complex as a powerful Mycobacterium tuberculosis immunogene: Biology, immune-pathogenicity, applications in diagnosis, and vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Lipoarabinomannan and related glycoconjugates: structure, biogenesis and role in Mycobacterium tuberculosis physiology and host-pathogen interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The Mycobacterial Cell Wall--Peptidoglycan and Arabinogalactan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Interpreting cell wall 'virulence factors' of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Phthiocerol dimycocerosates of M. tuberculosis participate in macrophage invasion by inducing changes in the organization of plasma membrane lipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The transpeptidase PbpA and non-canonical transglycosylase RodA of Mycobacterium tuberculosis play important roles in regulating bacterial cell lengths.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Peptidoglycan synthesis in Mycobacterium tuberculosis is organized into networks with varying drug susceptibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

An inhibitor of exported Mycobacterium tuberculosis glutamine synthetase selectively blocks the growth of pathogenic mycobacteria in axenic culture and in human monocytes: extracellular proteins as potential novel drug targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The α/β Hydrolase Fold Proteins of Mycobacterium tuberculosis, with Reference to their Contribution to Virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

IpdAB, a virulence factor in Mycobacterium tuberculosis, is a cholesterol ring-cleaving hydrolase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Catabolism of the Last Two Steroid Rings in Mycobacterium tuberculosis and Other Bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

In vivo virulence of Mycobacterium tuberculosis depends on a single homologue of the LytR-CpsA-Psr proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Design of Selective Substrates and Activity-Based Probes for Hydrolase Important for Pathogenesis 1 (HIP1) from Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mycobacterium tuberculosis impairs dendritic cell functions through the serine hydrolase Hip1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The mycobacterial cell envelope-lipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Virulence factors of the Mycobacterium tuberculosis complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

PE11, a PE/PPE family protein of Mycobacterium tuberculosis is involved in cell wall remodeling and virulence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Molecular structure of the Mycobacterium tuberculosis virulence factor, mycolic acid, determines the elicited inflammatory pattern.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Deletion of kasB in Mycobacterium tuberculosis causes loss of acid-fastness and subclinical latent tuberculosis in immunocompetent mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Lipomannan and lipoarabinomannan from a clinical isolate of Mycobacterium kansasii: novel structural features and apoptosis-inducing properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mycobacterium tuberculosis lipoarabinomannan-mediated IRAK-M induction negatively regulates Toll-like receptor-dependent interleukin-12 p40 production in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mannosylated lipoarabinomannans inhibit IL-12 production by human dendritic cells: evidence for a negative signal delivered through the mannose receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mechanism of phagolysosome biogenesis block by viable Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Cord factor as an invisibility cloak? A hypothesis for asymptomatic TB persistence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

TB research at UT-Houston--a review of cord factor: new approaches to drugs, vaccines and the pathogenesis of tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mycobacterium tuberculosis controls host innate immune activation through cyclopropane modification of a glycolipid effector molecule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Antibody bound to the surface antigen MPB83 of Mycobacterium bovis enhances survival against high dose and low dose challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Clearance and organ distribution of Mycobacterium tuberculosis lipoarabinomannan (LAM) in the presence and absence of LAM-binding immunoglobulin M.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Insights into Macrophage Autophagy in Latent Tuberculosis Infection: Role of Heat Shock Protein 16.3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Subunit Vaccines Consisting of Antigens from Dormant and Replicating Bacteria Show Promising Therapeutic Effect against Mycobacterium Bovis BCG Latent Infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Immunogenic potential of latency associated antigens against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Transmission of IgA and IgG monoclonal antibodies to mucosal fluids following intranasal or parenteral delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Induction of a protective response with an IgA monoclonal antibody against Mycobacterium tuberculosis 16kDa protein in a model of progressive pulmonary infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A novel human IgA monoclonal antibody protects against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Passive administration of purified secretory IgA from human colostrum induces protection against Mycobacterium tuberculosis in a murine model of progressive pulmonary infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Prophylactic effect of administration of human gamma globulins in a mouse model of tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Efficacy of Mycobacterial Cell Walls as a Vaccine against Airborne Tuberculosis in the Rhesus Monkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Enhancement of the immune response elicited with foot-and-mouth disease virus vaccines by an extract of the Mycobacterium sp. wall

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Immunotherapy of cancer: regression of established intradermal tumors after intralesional injection of mycobacterial cell walls attached to oil droplets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Immunotherapy with nonviable microbial components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Innate signaling by mycobacterial cell wall components and relevance for development of adjuvants for subunit vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Novel generation mycobacterial adjuvant based on liposome-encapsulated monomycoloyl glycerol from Mycobacterium bovis bacillus Calmette-Guérin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Comparison of different delivery systems of DNA vaccination for the induction of protection against tuberculosis in mice and guinea pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A single dose of a DNA vaccine encoding apa coencapsulated with 6,6'-trehalose dimycolate in microspheres confers long-term protection against tuberculosis in Mycobacterium bovis BCG-primed mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Rational design of adjuvants targeting the C-type lectin Mincle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Syringe free vaccination with CAF01 Adjuvated Ag85B-ESAT-6 in Bioneedles provides strong and prolonged protection against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Quality and Vaccine Efficacy of CD4+ T Cell Responses Directed to Dominant and Subdominant Epitopes in ESAT-6 from Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mycobacterium tuberculosis arabinomannan-protein conjugates protect against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Nasal boost with adjuvanted heat-killed BCG or arabinomannan–protein conjugate improves primary BCG-induced protection in C57BL/6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Enhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Phosphatidylinositol di-mannoside and derivates modulate the immune response to and efficacy of a tuberculosis protein vaccine against Mycobacterium bovis infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a Mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Adjuvant Potential of Poly-α-l-Glutamine from the Cell Wall of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The Immunology of CD1- and MR1-Restricted T Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The Conventional Nature of Non-MHC-Restricted T Cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The T-Cell Response to Lipid Antigens of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A novel antigen-carrier system: the Mycobacterium tuberculosis Acr protein carried by raw starch microparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Induction of strong immune response against a multicomponent antigen of Mycobacterium tuberculosis in BALB/c mice using PLGA and DOTAP adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Investigations of TB vaccine-induced mucosal protection in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Multicomponent antituberculous subunit vaccine based on immunodominant antigens of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Protective effect of a tuberculosis subunit vaccine based on a fusion of antigen 85B and ESAT-6 in the aerosol guinea pig model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

H1:IC31 vaccination is safe and induces long-lived TNF-α(+)IL-2(+)CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The development and preliminary evaluation of a new Mycobacterium tuberculosis vaccine comprising Ag85b, HspX and CFP-10:ESAT-6 fusion protein with CpG DNA and aluminum hydroxide adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Human immune recognition-based multicomponent subunit vaccines against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Protective immunity against Mycobacterium bovis induced by vaccination with Rv3109c--a member of the esat-6 gene family.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in infected mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Enhanced effect of BCG vaccine against pulmonary Mycobacterium tuberculosis infection in mice with lung Th17 response to mycobacterial heparin-binding hemagglutinin adhesin antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Re-formulation of selected DNA vaccine candidates and their evaluation as protein vaccines using a guinea pig aerosol infection model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Induction of immunity against experimental tuberculosis with mycobacterial mannophosphoinositides encapsulated in liposomes containing lipid A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

DNA vaccines against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

The 19-kD antigen and protective immunity in a murine model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Vaccination of guinea pigs with DNA encoding Ag85A by gene gun bombardment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Novel bacterial delivery system with attenuated Salmonella typhimurium carrying plasmid encoding Mtb antigen 85A for mucosal immunization: establishment of proof of principle in TB mouse model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

DNA vaccine using Mycobacterium bovis Ag85B antigen induces partial protection against experimental infection in BALB/c mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A combined DNA vaccine-prime, BCG-boost strategy results in better protection against Mycobacterium bovis challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Coadministration of interleukin 2 plasmid DNA with combined DNA vaccines significantly enhances the protective efficacy against Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Combined DNA vaccines formulated either in DDA or in saline protect cattle from Mycobacterium bovis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A DNA prime-live vaccine boost strategy in mice can augment IFN-gamma responses to mycobacterial antigens but does not increase the protective efficacy of two attenuated strains of Mycobacterium bovis against bovine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Immune responses and protective efficacy of the gene vaccine expressing Ag85B and ESAT6 fusion protein from Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A novel DNA vaccine containing multiple TB-specific epitopes casted in a natural structure (ECANS) confers protective immunity against pulmonary mycobacterial challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Combined DNA vaccines formulated in DDA enhance protective immunity against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mixed immune response induced in rodents by two naked DNA genes coding for mycobacterial glycosylated proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Boosting with a DNA vaccine expressing ESAT-6 (DNAE6) obliterates the protection imparted by recombinant BCG (rBCGE6) against aerosol Mycobacterium tuberculosis infection in guinea pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Elicitation of efficient, protective immune responses by using DNA vaccines against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

An ESAT-6:CFP10 DNA vaccine administered in conjunction with Mycobacterium bovis BCG confers protection to cattle challenged with virulent M. bovis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Efficacy of DNA-hsp65 vaccination for tuberculosis varies with method of DNA introduction in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Improve protective efficacy of a TB DNA-HSP65 vaccine by BCG priming.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Protective efficacy induced by Mycobacterium bovis bacille Calmette-Guèrin can be augmented in an antigen independent manner by use of non-coding plasmid DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Cloning of the gene encoding a 22-kilodalton cell surface antigen of Mycobacterium bovis BCG and analysis of its potential for DNA vaccination against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Vaccination of mice and cattle with plasmid DNA encoding the Mycobacterium bovis antigen MPB83.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Vaccination with DNA vaccines encoding MPB70 or MPB83 or a MPB70 DNA prime-protein boost does not protect cattle against bovine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Viral vectors as vaccine platforms: deployment in sight

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Live bacterial vaccine vectors: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Immunization with a bivalent adenovirus-vectored tuberculosis vaccine provides markedly improved protection over its monovalent counterpart against pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Enhanced protection against tuberculosis by vaccination with recombinant BCG over-expressing HspX protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Recombinant BCG Tokyo (Ag85A) protects cynomolgus monkeys (Macaca fascicularis) infected with H37Rv Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Immune responses and protective efficacy induced by 85B antigen and early secreted antigenic target-6 kDa antigen fusion protein secreted by recombinant bacille Calmette-Guérin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Immunogenicity of recombinant Mycobacterium bovis bacille Calmette-Guèrin clones expressing T and B cell epitopes of Mycobacterium tuberculosis antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Cellular and humoral immunogenicity of recombinant Mycobacterium smegmatis expressing Ag85B epitopes in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Protective efficacy against tuberculosis of ESAT-6 secreted by a live Salmonella typhimurium vaccine carrier strain and expressed by naked DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Subcutaneous administration of modified vaccinia virus Ankara expressing an Ag85B-ESAT6 fusion protein, but not an adenovirus-based vaccine, protects mice against intravenous challenge with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Heterologous boosting of recombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Vesicular Stomatitis Virus-Vectored Multi-Antigen Tuberculosis Vaccine Limits Bacterial Proliferation in Mice following a Single Intranasal Dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Protective effect of a lipid-based preparation from Mycobacterium smegmatis in a murine model of progressive pulmonary tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Induction of a specific strong polyantigenic cellular immune response after short-term chemotherapy controls bacillary reactivation in murine and guinea pig experimental models of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Outer membrane vesicles as platform vaccine technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Bacterial outer membrane vesicles and vaccine applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mycobacterial extracellular vesicles and host pathogen interactions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mycobacterium tuberculosis Pst/SenX3-RegX3 Regulates Membrane Vesicle Production Independently of ESX-5 Activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mycobacteria release active membrane vesicles that modulate immune responses in a TLR2-dependent manner in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mycobacterial membrane vesicles administered systemically in mice induce a protective immune response to surface compartments of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Protective capacity of proteoliposomes from Mycobacterium bovis BCG in a mouse model of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mycobacterium smegmatis proteoliposome induce protection in a murine progressive pulmonary tuberculosis model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Characterization of the Mycobacterium tuberculosis proteome by liquid chromatography mass spectrometry-based proteomics techniques: a comprehensive resource for tuberculosis research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Proteomic definition of the cell wall of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Mycobacterium tuberculosis functional network analysis by global subcellular protein profiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Comparative lipidomics of drug sensitive and resistant Mycobacterium tuberculosis reveals altered lipid imprints.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Insights into Interactions of Mycobacteria with the Host Innate Immune System from a Novel Array of Synthetic Mycobacterial Glycans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Glycerol monomycolate is a novel ligand for the human, but not mouse macrophage inducible C-type lectin, Mincle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Divergent effects of mycobacterial cell wall glycolipids on maturation and function of human monocyte-derived dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Recognition of Mycobacterial Lipids by Immune Receptors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Progress and challenges in TB vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Dissecting the mycobacterial cell envelope and defining the composition of the native mycomembrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

Phenolic glycolipids of Mycobacterium bovis: new structures and synthesis of a corresponding seroreactive neoglycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

7 January 2021

Tumor necrosis factor (cachectin) mediates induction of cachexia by cord factor from mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

7 January 2021

Effective nonliving vaccine against experimental tuberculosis in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

7 January 2021

Immunogenicity of cell walls from various mycobacteria against airborne tuberculosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2019.01.003

7 January 2021

10.1016/J.TUBE.2019.01.003

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30948174%20AND%20SRC:MED&resulttype=core&format=json

2 May 2020

1 reference